lifestyle.militaryparenting.org

Author: LEADS BIOLABS CO., LTD.

Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape

May 11, 2026
LBL-047 Prioritized for Clinical Development in Sjögren’s Disease, Systemic Lupus Erythematosus, and Dermatomyositis

May 5, 2026
Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

April 21, 2026
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

April 9, 2026